Efficacy Of Sorafenib For Advanced Hepatocellular Carcinoma Patients Refractory To Transarterial Chemoembolization

Purpose: To evaluate the efficacy and safety of sorafenib for the treatment of patients with advanced hepatocellular carcinoma(HCC)refractory to TACE.Methods: We retrospectively analyzed 61 advanced HCC patients refractory to TACE between April 2009 and April 2014 at our institution.Thrity patients received sorafenib and 31 received supporting treatment.The oral administration of sorafenib was started at 400 mg twice daily after diagnosed TACE-refractory by image.All patients attended follow-up every 4-6 weeks,The clinical response was assessed according to the modified Response Evaluation Criteria for Solid Tumors(m RECIST)criteria during the follow-up period.OS and PFS was the primary endpoint of the study,The secondary endpoints were Disease Control Rate(DCR)and Adverse Events(AE).All statistical analyses were performed with SPSS 17.0.Categorical variables were compared by chi-squared test.Survival curves were compared according to the Kaplan-Meier method.All tests were considered significant at p<0.05.Results: 1.There were no statistically significant differences in any of the baseline characteristics.The median OS were 17.9(95% CI 11.1–24.7)months and 7.1(95% CI 4.3–9.9)months respectively,p <0.001;The median PFS in treatment group and control group were 9.3(95% CI 8.5–10.1)months and 3.4(95% CI 2.0–4.8)months respectively,p <0.001.2.The DCR in treatment group and control group were 73.4% VS 51.6% respectively,p=0.08.There were no patients in the control group experienced an grade 3 or above AE,but in the treatment group,there were two patients experienced severe AE(1 patient grade 3 hand-foot syndrome;1 patient,diarrhea).18 patients required a sorafenib dose reduction because of AE,such as diarrhea,hand-foot syndrome,or rashes,and treatment was discontinued in 5 patients because of adverse events,such as hand-foot syndrome,diarrhea or rashes.Conclusions: 1.sorafenib significantly improved OS and PFS in patients with advanced HCC refractory to TACE and has good safety2.sorafenib was not significant improve DCR...